Skip to main content

Clinical Trials Using Palbociclib

Review the clinical trials studying palbociclib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-38 of 38

A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer or Metastatic Melanoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Palbociclib, Bortezomib, Dexamethasone, and Doxorubicin for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia, RELPALL2 Study
Status: Active
Location: Lucile Packard Children's Hospital Stanford University, Palo Alto, California
Palbociclib with Pembrolizumab for the Treatment of Patients with Locally Advanced, Metastatic or Unresectable Sarcomas
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Palbociclib or Tazemetostat in Combination with CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Status: Active
Location: UPMC Hillman Cancer Center Erie, Erie, Pennsylvania
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Palbociclib and Sorafenib, Decitabine, Dexamethasone or Venetoclax in Treating Patients with Recurrent or Refractory Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Palbociclib and Gedatolisib in Treating Patients with Advanced Solid Tumors or Lung, Pancreatic, or Head and Neck Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status: Active
Location: 450 locations
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
Status: Active
Location: 2 locations